Legend Biotech Schedules Q1 2026 Earnings Call Amid CAR-T Expansion Push
Event summary
- Legend Biotech will host an investor call on May 12, 2026 at 8:00 AM ET to discuss Q1 2026 results.
- The company is the largest standalone cell therapy firm with over 2,900 employees.
- CARVYKTI®, its lead CAR-T therapy for multiple myeloma, is co-developed with Johnson & Johnson.
- Legend aims to expand patient access and therapeutic potential of CARVYKTI while developing new cell therapies.
The big picture
Legend Biotech is positioning itself as a leader in the CAR-T cell therapy space, leveraging its partnership with Johnson & Johnson to expand CARVYKTI’s reach. The company’s focus on building an end-to-end cell therapy platform reflects broader industry trends toward vertically integrated biotech models. With over 2,900 employees, Legend is scaling operations to support both commercialization and R&D, but must navigate increasing competition in the oncology space.
What we're watching
- Revenue Growth
- Whether Legend Biotech can sustain CARVYKTI’s commercial momentum amid competitive pressures.
- Pipeline Development
- The pace at which Legend advances its next-generation cell therapy candidates beyond CAR-T.
- Partnership Dynamics
- How Johnson & Johnson’s collaboration impacts Legend’s long-term strategic independence.
Related topics